S&P 500   3,367.49 (-0.37%)
DOW   29,202.51 (-0.67%)
QQQ   234.45 (-0.08%)
AAPL   317.81 (-2.20%)
FB   217.35 (+1.48%)
MSFT   186.99 (+0.88%)
AMZN   2,155.86 (+0.98%)
CGC   22.41 (+1.26%)
BABA   219.06 (-0.26%)
MU   57.93 (-0.99%)
AMD   57.89 (+4.66%)
T   38.22 (-0.08%)
ACB   1.63 (+3.16%)
F   8.05 (-0.62%)
BAC   34.26 (-1.69%)
GILD   67.01 (-0.83%)
S&P 500   3,367.49 (-0.37%)
DOW   29,202.51 (-0.67%)
QQQ   234.45 (-0.08%)
AAPL   317.81 (-2.20%)
FB   217.35 (+1.48%)
MSFT   186.99 (+0.88%)
AMZN   2,155.86 (+0.98%)
CGC   22.41 (+1.26%)
BABA   219.06 (-0.26%)
MU   57.93 (-0.99%)
AMD   57.89 (+4.66%)
T   38.22 (-0.08%)
ACB   1.63 (+3.16%)
F   8.05 (-0.62%)
BAC   34.26 (-1.69%)
GILD   67.01 (-0.83%)
S&P 500   3,367.49 (-0.37%)
DOW   29,202.51 (-0.67%)
QQQ   234.45 (-0.08%)
AAPL   317.81 (-2.20%)
FB   217.35 (+1.48%)
MSFT   186.99 (+0.88%)
AMZN   2,155.86 (+0.98%)
CGC   22.41 (+1.26%)
BABA   219.06 (-0.26%)
MU   57.93 (-0.99%)
AMD   57.89 (+4.66%)
T   38.22 (-0.08%)
ACB   1.63 (+3.16%)
F   8.05 (-0.62%)
BAC   34.26 (-1.69%)
GILD   67.01 (-0.83%)
S&P 500   3,367.49 (-0.37%)
DOW   29,202.51 (-0.67%)
QQQ   234.45 (-0.08%)
AAPL   317.81 (-2.20%)
FB   217.35 (+1.48%)
MSFT   186.99 (+0.88%)
AMZN   2,155.86 (+0.98%)
CGC   22.41 (+1.26%)
BABA   219.06 (-0.26%)
MU   57.93 (-0.99%)
AMD   57.89 (+4.66%)
T   38.22 (-0.08%)
ACB   1.63 (+3.16%)
F   8.05 (-0.62%)
BAC   34.26 (-1.69%)
GILD   67.01 (-0.83%)
Log in

NASDAQ:ASNS - Arsanis Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$3.11
0.00 (0.00 %)
(As of 02/18/2020 01:17 PM ET)
Today's Range
$3.11
Now: $3.11
$3.11
50-Day Range
$3.11
MA: $3.11
$3.11
52-Week Range
$1.15
Now: $3.11
$28.69
VolumeN/A
Average Volume62,844 shs
Market Capitalization$45.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASNS
CUSIPN/A
Phone781-819-5704

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.50 million
Book Value$4.29 per share

Profitability

Net Income$-33,870,000.00

Miscellaneous

EmployeesN/A
Market Cap$45.53 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ASNS News and Ratings via Email

Sign-up to receive the latest news and ratings for ASNS and its competitors with MarketBeat's FREE daily newsletter.


Arsanis (NASDAQ:ASNS) Frequently Asked Questions

What is Arsanis' stock symbol?

Arsanis trades on the NASDAQ under the ticker symbol "ASNS."

How were Arsanis' earnings last quarter?

Arsanis Inc (NASDAQ:ASNS) released its earnings results on Friday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.02. View Arsanis' Earnings History.

Has Arsanis been receiving favorable news coverage?

News coverage about ASNS stock has trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arsanis earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near term. View News Stories for Arsanis.

Who are some of Arsanis' key competitors?

What other stocks do shareholders of Arsanis own?

Who are Arsanis' key executives?

Arsanis' management team includes the folowing people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Mr. Michael P. Gray CPA, M.B.A., MBA, CPA, Pres, CEO, CFO & Director (Age 48)
  • Dr. Eszter Nagy, Co-Founder (Age 53)
  • Mr. David S. Mantus, Chief Devel. Officer (Age 56)
  • Ms. Fraser Leslie BSc, MSB, CBiol, Sr. VP of Technical Operations

When did Arsanis IPO?

(ASNS) raised $50 million in an initial public offering on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO.

What is Arsanis' stock price today?

One share of ASNS stock can currently be purchased for approximately $3.11.

How big of a company is Arsanis?

Arsanis has a market capitalization of $45.53 million and generates $3.50 million in revenue each year. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. View Additional Information About Arsanis.

What is Arsanis' official website?

The official website for Arsanis is http://www.arsanis.com/.

How can I contact Arsanis?

Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]


MarketBeat Community Rating for Arsanis (NASDAQ ASNS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  347 (Vote Underperform)
Total Votes:  613
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Commodities

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel